Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 15/20 | 0.61 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826019 | 0.89 | KLKB1 (0.68) | KLKB1CARM1 | |
| SCHEMBL17064709 | 0.89 | KLKB1 (0.68) | KLKB1CARM1 | |
| SCHEMBL31067474 | 0.85 | KLKB1 (0.84) | KLKB1CARM1 | |
| SCHEMBL17064713 | 0.85 | KLKB1 (0.84) | KLKB1CARM1 | |
| SCHEMBL28111097 | 0.84 | KLKB1 (0.59) | KLKB1CARM1 | |
| SCHEMBL17064626 | 0.83 | KLKB1 (0.69) | KLKB1CARM1 | |
| SCHEMBL14565461 | 0.81 | CARM1 (0.86) | KLKB1CARM1 | |
| SCHEMBL18604968 | 0.79 | KLKB1 (0.89) | KLKB1CARM1F2F10PRSS1 | |
| SCHEMBL31067583 | 0.79 | KLKB1 (0.89) | KLKB1CARM1F2F10PRSS1 | |
| SCHEMBL18604749 | 0.79 | KLKB1 (0.72) | KLKB1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885CARM1 4304/4885F2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.